MS Fatigue and tDCS on Fatigue in Multiple Sclerosis
The Effect of Home-Based Transcranial Direct Current Stimulation on Fatigue in Multiple Sclerosis
We could not find results for this trial
What it found
We found no results in the registry or in papers.
This trial finished 3 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Placebo
- Real left prefrontal tDCS - sham
- Sham - Real left prefrontal tDCS
What it measured
Main measures
Tiredness
12 weeks
Thinking and memoryFatigue
Other measures (5)
Depression
12 weeks
Mood and sleepAnxiety
12 weeks
Mood and sleepAlexithymia
before and after each stimulation period (active and simulated) and four weeks later (four weeks after the last stimulation session of each period).
MSQOL scale
12 weeks
Quality of life (reported by participants)Cognitive functions
12 weeks
Thinking and memoryQuality of life (reported by participants)
Who could take part
MS (type not specified) · 18 to 75
Show the full criteria
Inclusion criteria
* Definite MS diagnosis according to the 2017 McDonald criteria * Fatigue since more than 6 months as assessed by fatigue severity scale (FSS>5) * Age between 18 and 75 years. * Stable pharmacological and physical treatment since at least one month * Affiliation to the social security regimen * Signature of the informed consent * Ability of the patient to understand the instructions for use of the pacemaker to ensure safe use
Exclusion criteria
* Relapses within the last two months * Active medical device implanted * Intracranial metal implants * Craniotomy, cranial trepanation, aneurysm * Uncontrolled epilepsy * Non-weaned alcoholism, sleep debt * Expanded disability status scale ≥ 6.5 * Severe depression based on Beck Depression inventory (BDI>19) * Daytime sleepiness based on Epworth Sleepiness Scale (ESS> 11) * Other neurologic and psychiatric diseases * Known pregnancy by the investigator or breastfeeding * Physical or mental incapacity to give informed consent * Participation in another study (exclusion period following a previous study should be ≥ 6 months) * Patients on AME * Patients under legal protection * Prisoners
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The available therapeutic strategies for Multiple Sclerosis (MS)-related symptoms are usually faced with limited efficacy and numerous side effects. Patients with MS frequently suffer from fatigue, affective symptoms, and cognitive deficits.
Loading reviews and guidelines…
History
Started
Sept 2022
Main results due
Apr 2023
Finished
Apr 2023